Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

Dupilumab significantly reduced severe asthma exacerbations and SCS prescriptions vs omalizumab in patients using add-on maintenance therapy.

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in ...

The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Treatment with dupilumab led to significant improvements in remission in patients with bullous pemphigoid, an autoimmune blistering skin disease.

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...

In a recent study investigators established that extended dupilumab therapy-up to three years-is highly effective in the ...

Study C of the phase 3 LIBERTY-CUPID trial evaluated dupilumab as add-on therapy to standard of care antihistamines in biologic-naïve patients with CSU who remained symptomatic despite antihistamine ...

13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...

Researchers have been able to identify whether patients with atopic dermatitis who receive dupilumab treatment will respond ...